2012 global pain market $61.6bn

A report released this month estimates that the global market for pain relieving drugs will reach $61.6 billion this year, with forecast steady growth over the next decade,

The World Pain Relieving Drug Market 2012-2022report by Visiongain states that market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes. It predicts rising revenues from the launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules.

The report notes that drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs.
It predicts success for those drug delivery technologies and applications that provide improved clinical efficacy, patient convenience and treatment compliance.

Phosphagenics' pipeline includes a TPM/Oxycodone patch (world-first transdermal delivery of oxycodone), TPM/diclofenc gel (ie. Voltaren competitor with 4 times the efficacy), TPM/lidocaine (Xylocaine local anaesthetic competitor with 450% more penetration) and TPM/Oxycodone gel (for localised pain - there are currently no topical opiods on the market). It's an impressive pipeline, providing significant exposure to this huge market.

http://www.prnewswire.co.uk/news-releases/painkillers-market-will-reach-616-billion-in-2012-visiongain-report-predicts-168754356.html

http://www.marketresearch.com/Visiongain-v1531/Drug-Delivery-Technologies-Commercial-Prospects-6841733/